A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancerResearch in context by R. Tuli, S.L. Shiao, N. Nissen, M. Tighiouart, S. Kim, A. Osipov, M. Bryant, L. Ristow, V.R. Placencio-Hickok, D. Hoffman, S. Rokhsar, K. Scher, S.J. Klempner, P. Noe, M.J. Davis, A. Wachsman, S. Lo, L. Jamil, H. Sandler, S. Piantadosi, A. Hendifar

Get full text